Mounjaro plateau: stop, increase, maintain, or rethink?

What is a plateau and when does one matter?

A plateau on Mounjaro is a period during which weight has stopped declining despite ongoing treatment. Some plateaus are normal and expected — weight loss on tirzepatide is not linear, and the rate of loss typically slows after the first six months even at therapeutic doses. [1] Others represent genuine inadequate response or biological resistance. The clinical task is to distinguish between these before making a dose or treatment decision.

A practical definition: if weight has not declined by at least 2% over twelve weeks at a stable dose, a plateau is real and worth addressing. If the plateau is shorter, give it more time before acting.

Option 1: increase the dose

Tirzepatide is available at 2.5, 5, 7.5, 10, 12.5, and 15 mg. The dose-response relationship is real — higher doses produce greater appetite suppression and greater weight loss in trials. [1] If you are not at maximum tolerated dose and the plateau is genuine, dose escalation is the most evidence-backed next step.

The caveats: dose escalation increases gastrointestinal side-effect risk, particularly nausea and constipation. It requires clinician oversight. And it should not be applied indefinitely — if there is inadequate response at 15 mg after twelve to sixteen weeks, the question of whether tirzepatide is the right agent for this patient becomes relevant.

Option 2: maintain the current dose

If weight loss has been substantial and the plateau represents a new biological equilibrium rather than inadequate response, maintaining the current dose is appropriate. SURMOUNT-4 showed that continuing tirzepatide maintains weight loss and prevents regain, even when active loss has slowed. [2] Maintenance is not failure — it is clinical success if the health gains of weight loss are being preserved.

The NICE criterion for continuation beyond two years is maintenance of at least 5% weight loss from baseline at two years of treatment. [3] A patient who has lost 15% and plateaued clearly meets this criterion.

Option 3: stop

Stopping at a plateau is a reasonable decision if the patient has reached a clinically acceptable weight and metabolic state, tolerability issues are significant, or ongoing treatment is not sustainable. The risk is regain — SURMOUNT-4 shows approximately 14% body weight regained over one year after stopping. [2] This is a manageable risk with a proper exit plan, not a reason to continue indefinitely against a patient's wishes. See stopping GLP-1s after reaching target weight.

Option 4: rethink the approach

If a plateau is occurring despite optimal dosing, the question to ask is whether the underlying drivers of weight gain have been addressed or merely suppressed. GLP-1 medication suppresses appetite; it does not correct poor sleep, alcohol excess, severe stress load, or a dietary pattern that is fundamentally unsuited to the patient's satiety biology. A plateau at therapeutic dose may be the medication telling you that pharmacology alone is not sufficient.

This is also the moment to consider whether body composition is the more relevant variable. A patient whose weight has plateaued but who has significantly improved lean mass, waist, and metabolic markers has had a successful clinical outcome — the scale plateau is misleading the assessment.

What is not a legitimate option

Persistent dose escalation without clinical oversight. Stopping abruptly in frustration without a plan. Switching to severe caloric restriction while on the medication, which risks lean mass loss and micronutrient deficiency. And continuing indefinitely with a drug that is not working, because stopping feels like failure.